肿瘤细胞治疗研究
英文原题：'Living drugs' target CD70 in advanced renal tumors.
'Living drugs' target CD70 in advanced renal tumors.
针对实体瘤的细胞疗法面临三大障碍：持久性低、特异性不足和成本高昂。
针对实体瘤的细胞疗法面临三大障碍：持久性低、特异性不足和成本高。在最近的一项研究中，Pal等人通过使用针对稳定抗原的新型“持久性调谐”同种异体嵌合抗原受体（CAR）T细胞，在肾癌中应对了这些挑战。
Cellular therapies against solid tumors face three major barriers: low persistence, insufficient specificity, and high costs. In a recent study, Pal et al. tackle these challenges in kidney cancer by using novel, 'persistence-tuned' allogeneic chimeric antigen receptor (CAR) T cells directed against a stable antigen.
MEMBER ACCOUNT
登录成功会直接打开下一页。
